Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Status:
Terminated
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
An unmet medical need exists for the successful therapy of patients with advanced
hepatocellular and biliary tract malignances, with few and short lived disease responses to
chemotherapy for both advanced stage hepatic and biliary carcinomas. Pre-clinical data shows
cooperative antitumor activity between an epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor and taxanes. The efficacy of erlotinib in combination with docetaxel will be
assessed in this trial.